All Posts
RCT: Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer.
24 Jun, 2021 | 09:41h | UTCLutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
[News release – not published yet] COVID-19 outpatient thrombosis prevention trial ends early – “Results suggest that not treating certain symptomatic but stable outpatients with anticoagulant or antiplatelet therapy may be the best course of action”.
23 Jun, 2021 | 10:32h | UTCCommentary: Antithrombotics No Help for Stable COVID-19 Outpatients: ACTIV-4b – TCTMD
Interactive Infographic | Interpreting a lateral flow SARS-CoV-2 antigen test – “This calculator demonstrates how interpreting a covid-19 lateral flow device (LFD) result varies according to the pre-test probability, and the sensitivity and specificity of the LFD used”.
23 Jun, 2021 | 10:29h | UTCInterpreting a lateral flow SARS-CoV-2 antigen test – The BMJ
Laboratory testing for suspected COVID-19 vaccine–induced (immune) thrombotic thrombocytopenia.
23 Jun, 2021 | 10:25h | UTC
Delta coronavirus variant: scientists brace for impact.
23 Jun, 2021 | 10:27h | UTCDelta coronavirus variant: scientists brace for impact – Nature
New Analysis reveals link between birthdays and COVID-19 spread during the height of the pandemic.
23 Jun, 2021 | 10:22h | UTCNews release: New Analysis reveals link between birthdays and COVID-19 spread during the height of the pandemic – Harvard Medical School
Original Study: Assessing the Association Between Social Gatherings and COVID-19 Risk Using Birthdays – JAMA Internal Medicine
Commentary on Twitter (thread – click for more)
The link between birthdays and Covid-19
Thread on our new study (w/ @CM_Whaley, Jon Cantor, Megan Pera) in @JAMAInternalMed
Using data on ~3M households, households in which a member had bday 2 wks prior were ~30% more likely to have a covid diagnosishttps://t.co/KHCvGAlvox
— Anupam Jena (@AnupamBJena) June 21, 2021
UNESCO and WHO urge countries to make every school a health-promoting school.
23 Jun, 2021 | 10:18h | UTCNews release: UNESCO and WHO urge countries to make every school a health-promoting school – World Health Organization
Guideline: WHO guideline on school health services – World Health Organization
Commentary: UNESCO and WHO Launch Initiative to Promote Healthier School Environments – Health Policy Watch
Commentary on Twitter (thread – click for more)
WHO and @UNESCO urge countries to make every school a health-promoting school, following the Global Standards for Health-promoting Schools that aim to ensure all schools promote life skills, cognitive & socioemotional skills & healthy lifestyles.https://t.co/qnMB3EprR8
— World Health Organization (WHO) (@WHO) June 22, 2021
The Risk of Allergic Reaction to SARS-CoV-2 Vaccines and Recommended Evaluation and Management: A Systematic Review, Meta-analysis, GRADE Assessment, and International Consensus Approach.
23 Jun, 2021 | 10:23h | UTC
AHA Scientific Statement: Obstructive Sleep Apnea and Cardiovascular Disease.
23 Jun, 2021 | 10:16h | UTCNews Release: Sleep apnea worsens heart disease, yet often untreated – American Heart Association
Cohort study: no association was found between statin therapy and cognitive decline or incident dementia in older adults.
23 Jun, 2021 | 10:14h | UTCCommentaries: Statin Therapy Not Associated With Cognitive Decline, Dementia in Older Adults, Study Says – American College of Cardiology AND Effect of Statins on Cognitive Decline and Dementia in Older Adults – American College of Cardiology
Review: Transcatheter treatment of valvular heart disease.
23 Jun, 2021 | 10:12h | UTCTranscatheter Treatment of Valvular Heart Disease: A Review – JAMA
Audio Clinical Review: Transcatheter Treatments of Valvular Heart Disease
Video: Transcatheter Aortic Valve Implantation (TAVI)
Video: Transcatheter Aortic Valve-in-Valve Procedure After Bioprosthetic Valve Failure
Video: Transcatheter Mitral Valve-in-Valve Procedure After Bioprosthetic Valve Failure
Video: Mitral Valve Transcatheter Edge-to-Edge Repair
Expert analysis | The global prevention of cardiovascular disease among people living with diabetes: leading with heart.
23 Jun, 2021 | 10:13h | UTCOriginal publication and resources: The Global Diabetes Compact – World Health Organization
See also: The WHO Global Diabetes Compact: a new initiative to support people living with diabetes – The Lancet Diabetes & Endocrinology (free registration required)
[Preprint] Rapid displacement of SARS-CoV-2 variant B.1.1.7 (Alpha) by B.1.617.2 (Delta) and P.1 (Gamma) in the United States.
22 Jun, 2021 | 10:12h | UTCRapid displacement of SARS-CoV-2 variant B.1.1.7 by B.1.617.2 and P.1 in the United States – medRxiv
Commentary on Twitter
🆕💥💥Preprint
📌B.1.617.2 Delta and P.1 are growing faster than B.1.1.7 & B.1.617.2 is growing faster than P.1 in the US
📌B.1.617.2 will soon be the dominant variant in the US
📌B.1.617.2 is growing more rapidly in counties with lower vaccination rateshttps://t.co/6Rf3p5N4ed pic.twitter.com/sVzyQRXn12— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) June 22, 2021
Editorial | Physiotherapists can reduce overuse by Choosing Wisely.
23 Jun, 2021 | 10:11h | UTCPhysiotherapists can reduce overuse by Choosing Wisely – Journal of Physiotherapy
See complete lists of low-value practices: Choosing Wisely U.S. / Choosing Wisely UK / Choosing Wisely Australia AND Choosing Wisely Canada
Ivermectin is the new hydroxychloroquine, take 2 – “Ivermectin shouldn’t be used to treat COVID-19 outside of the context of a well-designed clinical trial”.
22 Jun, 2021 | 10:08h | UTCIvermectin is the new hydroxychloroquine, take 2 – Science-Based Medicine
Related: [Preprint] Meta-analysis of RCT: Ivermectin for the treatment of COVID-19 – no effect on all-cause mortality, length of stay, or viral clearance AND M-A: Prophylaxis against Covid-19: 1 – no benefit from Hydroxychloroquine; 2 – as studies on ivermectin so far have been small, it remains very uncertain whether ivermectin reduces SARS-CoV-2 infection AND Therapeutics and COVID-19 | WHO guideline update advises Ivermectin should only be used to treat COVID-19 within clinical trials AND EMA advises against use of ivermectin for the prevention or treatment of COVID-19 outside randomized clinical trials AND FDA: Why you should not use Ivermectin to treat or prevent COVID-19 AND RCT: Ivermectin does not improve time to resolution of symptoms among adults with mild COVID-19 AND NIH Guideline Statement: “there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19” AND Video (5min): Ivermectin for COVID-19 | A Doctor Explains
Perspective | COVID-19: The rise and rise of Delta.
22 Jun, 2021 | 10:10h | UTCCOVID-19: The rise and rise of Delta – Sciblogs
2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis.
22 Jun, 2021 | 09:58h | UTC2021 MAGNIMS–CMSC–NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis – The Lancet Neurology (free registration required)
Commentary on Twitter
ONLINE FIRST: The 2021 MAGNIMS–CMSC–NAIMS international consensus recommendations on MRI in patients with multiple sclerosis provide updated guidance on how and when to use MRI for diagnosis, prognosis, and treatment monitoring of multiple sclerosishttps://t.co/bLnRo40tgw
— The Lancet Neurology (@TheLancetNeuro) June 15, 2021
Guidelines for reporting trial protocols and completed trials modified due to the COVID-19 pandemic and other extenuating circumstances: The CONSERVE 2021 Statement.
22 Jun, 2021 | 10:04h | UTC
Commentaries on Twitter
CONSERVE offers guidance that could help improve the transparency, quality, and completeness of reporting important modifications to trials in extenuating circumstances https://t.co/IiWgs7dtpQ
— JAMA (@JAMA_current) June 21, 2021
https://twitter.com/DrSherryPagoto/status/1407102563191824384
Case report: Multisystem inflammatory syndrome in an adult after SARS-CoV-2 infection.
22 Jun, 2021 | 10:04h | UTC
AGS publishes updated AGS Minimum Geriatrics Competencies for Graduating Medical Students.
22 Jun, 2021 | 09:59h | UTCNews release: AGS publishes updated AGS Minimum Geriatrics Competencies for Graduating Medical Students – American Geriatrics Society
Recommendations: Minimum Geriatric Competencies for Medical Students
Study shows overuse of levothyroxine in patients with subclinical hypothyroidism despite evidence of no benefit.
22 Jun, 2021 | 09:57h | UTCLevothyroxine Use in the United States, 2008-2018 (free for a limited period)
Editorial: Overuse of Levothyroxine in Patients With Subclinical Hypothyroidism: Time to “Leve”-Out-Thyroxine – JAMA Internal Medicine (free for a limited period)
Related: RCT: Levothyroxine does not reduce the risk of developing depressive symptoms in older adults with subclinical hypothyroidism (studies and guidelines on the subject)
Guideline synopsis: management of blood pressure in patients with chronic kidney disease not receiving dialysis.
22 Jun, 2021 | 10:00h | UTCOriginal guideline: KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease
Commentary: Guideline issued on blood pressure management in CKD – ACP Internist
Expert analysis: the ever-growing role of coronary artery calcium in primary prevention.
22 Jun, 2021 | 09:54h | UTC
Commentary on Twitter
New ACC Expert Analysis: The Ever-Growing Role of Coronary Artery Calcium in Primary Prevention.
More: https://t.co/GSsEqkoMbi @miguelcainzos23 @rblument1 @AndyGagel #ASCVD #cvPrev pic.twitter.com/7cUOAIArz9
— American College of Cardiology (@ACCinTouch) June 22, 2021
Increased transmissibility and global spread of SARS-CoV-2 variants of concern – “Estimated transmissibility increases of alpha 29% (95% CI: 24–33), beta 25% (95% CI: 20–30), gamma 38% (95% CI: 29–48) & delta 97% (95% CI: 76–117)”.
21 Jun, 2021 | 08:55h | UTC
Commentary on Twitter
NEW publication in Eurosurveillance
Increased transmissibility & global spread of #SARSCoV2 VOC & VOI
Estimated transmissibility increases of alpha 29% (95% CI: 24–33), beta 25% (95% CI: 20–30), gamma 38% (95% CI: 29–48) & delta 97% (95% CI: 76–117)
⬇️https://t.co/pmyfQMM78y pic.twitter.com/Xz3cOImRvc
— Maria Van Kerkhove (@mvankerkhove) June 17, 2021
National surveillance in England showed low risk of reinfection with Covid-19 – “There were 15,893 possible reinfections with SARS-CoV-2 identified up to 30 May 2021 in England throughout the pandemic, out of nearly 4 million people with confirmed infections. This is equivalent to around 0.4% cases becoming reinfected”.
21 Jun, 2021 | 08:56h | UTCNew national surveillance of possible COVID-19 reinfection, published by PHE – Public Health England
Related: Had COVID? You’ll probably make antibodies for a lifetime – Nature AND COVID-19 reinfection rate less than 1 percent for those with severe illness, study finds. AND Study shows low risk of SARS-CoV-2 reinfection 1 year after primary infection.